Researchers at King Khalid University have identified a small molecule, KS79356, that potently blocks the growth, invasion, and migration of triple-negative breast cancer cells by shutting down an enzyme called kynureninase, or KYNU, which sits at a critical junction of the tryptophan metabolic pathway. The discovery, published in the journal Medical Oncology, describes how the team combined computational drug discovery with laboratory validation in three breast cell lines to arrive at a lead compound that inhibits KYNU at nanomolar concentrations and, in doing so, disables an inflammatory signaling cascade long implicated in tumor progression. Because triple-negative breast cancer, or TNBC, lacks the estrogen, progesterone, and HER2 receptors that make other breast cancers vulnerable to targeted therapy, patients currently rely on chemotherapy and, more recently, immunotherapy combinations that deliver only modest and often transient benefits. The new work therefore adds a fresh molecular target and a chemically defined inhibitor to a therapeutic landscape that clinicians describe as one of the most challenging in oncology.
The study began with an analysis of KYNU’s crystal structure to map the residues that line its catalytic pocket, an exercise complemented by an AlphaFold-predicted full-length model that allowed the researchers to assess the enzyme’s architecture beyond the crystallized fragment. KYNU is a hydrolase in the kynurenine pathway, the major route by which the essential amino acid tryptophan is catabolized in mammals. The pathway has attracted intensifying attention in cancer biology because its intermediates modulate immune surveillance, oxidative stress, and cell proliferation, and because altered tryptophan metabolism has been documented in breast cancer patients as far back as the late 1960s. Kynurenine 3-monooxygenase, another enzyme on the same pathway, was previously shown to drive TNBC progression through beta-catenin signaling, while reduced KYNU expression has been linked to restrained proliferation in cutaneous squamous cell carcinoma. What remained poorly defined until now was whether pharmacologically targeting KYNU-mediated inflammatory signaling could produce a therapeutic effect in TNBC itself.
To find molecules capable of engaging the KYNU active site, the team performed a diversity-based high-throughput virtual screen of the ChemBridge compound library, ranking candidates by docking energy and then filtering them through protein–ligand interaction profiling and predicted ADMET properties, which describe a compound’s absorption, distribution, metabolism, excretion, and toxicity. The computational pipeline did not stop at static docking. Shortlisted complexes were subjected to molecular dynamics simulations in GROMACS, a widely used open-source package that tracks the motion of atoms over time under realistic physical forces, allowing the researchers to observe whether candidate ligands remained seated in the binding pocket or drifted away as the protein flexed. Binding free energies were then estimated with the gmx_MMPBSA tool, an end-state free energy method that decomposes the thermodynamic contributions of a protein–ligand complex and is regarded as a more rigorous indicator of affinity than docking scores alone. The lead compound KS79356 stood out with a docking score of −7.8 kcal/mol, exceptionally stable interaction geometry maintained at a root-mean-square deviation of approximately 0.075 nanometers, and a calculated binding free energy of −23.93 kcal/mol, figures that together indicated a durable and energetically favorable engagement with the enzyme.
Experimental validation followed in three cell lines: SUM159 and MDA-MB-231, both established TNBC models, and HBL-100, a non-tumorigenic breast cell line used to assess selectivity. KS79356 inhibited KYNU enzymatic activity with a half-maximal inhibitory concentration of 63.7 nanomolar, a potency that places the compound in the same range as many clinically approved enzyme inhibitors. When tested on cell proliferation, the molecule suppressed the growth of SUM159 cells with a GI50 of 233 nanomolar and MDA-MB-231 cells with a GI50 of 450.8 nanomolar, while sparing HBL-100 cells to a markedly greater degree, a differential toxicity profile that suggests the compound’s effects are concentrated in malignant tissue rather than healthy breast epithelium. The authors note that the compound also carried favorable ADMET characteristics predicted by a machine learning platform designed to evaluate large chemical libraries, an early but encouraging sign for downstream developability.
The mechanistic heart of the study lies in what KS79356 does to inflammatory signaling. Tumor necrosis factor alpha, or TNF-α, is a pro-inflammatory cytokine that activates the transcription factor nuclear factor kappa B, NFκB, a master regulator of survival, proliferation, and immune genes whose chronic activation in tumors promotes growth, metastasis, and chemotherapy resistance. NFκB signaling in turn drives expression of CD44, a cell surface glycoprotein best known as a marker of cancer stem-like cells that promotes tumorigenicity, cell motility, hyaluronan production, and metastatic seeding in bone, and which has repeatedly been associated with poor prognosis in breast cancer. CD44 signaling feeds forward into Akt, a kinase central to the phosphatidylinositol 3-kinase survival pathway, creating an axis — TNF-α to NFκB to CD44 to phosphorylated Akt — that functions as a self-reinforcing engine of tumor aggressiveness. Using Western blot analysis of phosphorylated proteins, the researchers showed that KS79356 downregulated TNF-α–induced phosphorylation of NFκB, suppressed CD44 expression, and reduced Akt phosphorylation in TNBC cells, effectively cutting the communication lines along which inflammatory signals translate into malignant behavior.
The functional consequences of that signaling shutdown were substantial. Treated TNBC cells showed reduced proliferation, diminished capacity to invade through extracellular matrix, and a striking impairment in trans-endothelial migration, the process by which cancer cells squeeze through the endothelial lining of blood vessels to enter the circulation and seed distant metastases. Trans-endothelial migration is one of the earliest and most decisive steps of the metastatic cascade, and its inhibition suggests that KYNU blockade could, in principle, limit not only primary tumor growth but also the spread that makes TNBC lethal. At the same time, flow cytometric analysis revealed that KS79356 induced both early and late apoptosis, pushing cancer cells down programmed death pathways rather than merely halting their division. The combination of cytostatic and cytotoxic effects, delivered through a single upstream metabolic target, illustrates the appeal of enzyme inhibitors that sit at convergence points of multiple oncogenic pathways.
The choice of KYNU as a target also connects the work to a broader and rapidly expanding literature on the kynurenine pathway in cancer immunology. The pathway’s metabolites influence both innate and adaptive immunity and have been implicated in immune-related diseases ranging from autoimmune endocrinopathies to chronic inflammation. In tumors, kynurenine pathway activity can help create an immunosuppressive microenvironment, and the pathway has been described as presenting multi-faceted metabolic vulnerabilities that cancer cells cannot easily compensate for. Reviews of clinical research and trials in breast cancer have highlighted the kynurenine pathway as an emerging therapeutic frontier, and the present study is among the first to move from that associative evidence to a chemically validated, mechanistically annotated inhibitor in TNBC models. The authors position KYNU itself as a novel therapeutic target, distinguishing their approach from earlier efforts aimed at other pathway enzymes such as indoleamine 2,3-dioxygenase and kynurenine 3-monooxygenase.
The computational methodology deserves attention in its own right, both for its rigor and for what it suggests about the future pace of drug discovery. The study’s pipeline — structure-based virtual screening, interaction profiling, molecular dynamics in GROMACS, and MM/PBSA free energy calculations — represents a now-standard but still powerful strategy for identifying chemical starting points without the expense of screening hundreds of thousands of compounds experimentally. The team has deployed similar approaches previously, including the identification of dual PI3K/AKT pathway inhibitors for acute myeloid leukemia and a selective TGFβ receptor II kinase inhibitor for breast cancer, and the same group’s earlier work on inflammatory attenuation via the Akt/NFκB pathway foreshadowed the mechanistic hypothesis tested here. The convergence of those threads in KS79356 illustrates how iterative, computationally guided campaigns can accumulate mechanistic insight across related signaling pathways and disease contexts.
Important caveats remain. All of the reported efficacy data derive from cell culture; no xenograft, syngeneic, or patient-derived models were included, and no pharmacokinetic or toxicity studies in animals have been performed. TNBC is notoriously heterogeneous, and the two cell lines used, while among the most widely studied, do not capture the full molecular diversity of the disease, including the immune-cold and immune-hot subtypes that respond differently to existing immunotherapies such as the atezolizumab and pembrolizumab combinations approved in recent years. The nanomolar GI50 values observed in vitro will need to translate into achievable and tolerable plasma exposures in vivo, a hurdle that eliminates many promising enzyme inhibitors. Nevertheless, the selectivity against HBL-100 cells, the clean biochemical potency, and the coherent mechanistic story linking KYNU inhibition to reduced NFκB–CD44–Akt signaling give the compound a credible foundation for preclinical development.
For a disease that accounts for roughly fifteen to twenty percent of breast cancers and disproportionately affects younger women and, in some populations, carries a hereditary burden linked to BRCA mutations, every new molecular vulnerability matters. The current therapeutic arsenal for metastatic TNBC — anthracyclines, taxanes, platinum agents, antibody–drug conjugates such as sacituzumab govitecan, and immune checkpoint inhibitors — has extended survival but rarely changes the long-term trajectory of the disease. A metabolic enzyme inhibitor that simultaneously blunts inflammatory signaling, stem-like cell marker expression, survival kinase activity, invasion, and intravasation would represent a genuinely different modality, one that attacks the tumor microenvironment’s inflammatory fuel supply rather than its DNA or microtubules. The King Khalid University team, funded through the institution’s Large Research Groups Program and supported by collaborators at SMARTBIO LABS in Chennai and Si-BIOLEAD in Arkansas, has provided the first pharmacological proof of concept that KYNU can be drugged to antitumor effect. The next chapter — confirming those effects in animal models and optimizing KS79356’s drug-like properties — will determine whether this computational lead can complete the long journey from docking screen to clinic.
Subject of Research: Inhibition of kynureninase (KYNU) as a therapeutic strategy for triple-negative breast cancer
Subject of Research: Cancer
Article Title: KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis
Article References: Alghamdi, M. A., Deshpande, H., Kumar, A., & Rajagopalan, P. (2026). KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB–CD44–Akt signaling axis. Medical Oncology, 43(10), Article 259. https://doi.org/10.1007/s12032-026-03377-5
Image Credits: AI Generated
DOI: 10.1007/s12032-026-03377-5
Keywords: triple-negative breast cancer, kynureninase (KYNU), KS79356, tryptophan metabolism, NFκB, CD44, p-Akt, TNF-α signaling, apoptosis, metastasis, high-throughput virtual screening, molecular dynamics simulations
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 6, 2026). Novel kynureninase inhibitor KS79356 slows triple-negative breast cancer progression. Scienmag. https://scienmag.com/novel-kynureninase-inhibitor-ks79356-slows-triple-negative-breast-cancer-progression/
Nathaniel Bowman. “Novel kynureninase inhibitor KS79356 slows triple-negative breast cancer progression.” Scienmag, 6 September 2026, https://scienmag.com/novel-kynureninase-inhibitor-ks79356-slows-triple-negative-breast-cancer-progression/. Accessed 6 September 2026.
Nathaniel Bowman. “Novel kynureninase inhibitor KS79356 slows triple-negative breast cancer progression.” Scienmag. September 6, 2026. https://scienmag.com/novel-kynureninase-inhibitor-ks79356-slows-triple-negative-breast-cancer-progression/
Copy citation Download RIS
Tags: AlphaFold protein modeling in drug developmentcomputational drug discovery in oncologyenzyme structure analysis for drug designenzyme structure-based drug designimmunotherapy resistance in breast cancerinflammation and tumor progressioninflammatory signaling in breast cancerKS79356 enzyme inhibitorKS79356 kynureninase inhibitorKYNU enzyme inhibitionKYNU enzyme role in tumor progressionKynureninase inhibitor in breast cancermolecular mechanisms of tumor invasionnanomolar potency KYNU inhibitorsnovel molecular targets in triple-negative breast cancernovel treatments for aggressive breast cancerssmall-molecule cancer therapeuticssmall-molecule inhibitors for cancer therapytargeted therapy for TNBCtriple negative breast cancer treatmenttriple-negative breast cancertryptophan metabolic pathwaytryptophan metabolic pathway in cancer
